Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting

BOTHELL, Wash.--()--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 7, 2015 during the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, FL. Members of Seattle Genetics’ management team and an industry expert will discuss data being presented at the conference from multiple programs, most notably ADCETRIS® (brentuximab vedotin), SGN-CD33A (vadastuximab talirine) and SGN-CD19A (denintuzumab mafodotin).

The event will take place from approximately 8:15 p.m. to 9:15 p.m. Eastern Time. The webcast will be available live and for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin) is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 55 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD33A (vadastuximab talirine), SGN-CD19A (denintuzumab mafodotin), SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

Contacts

Seattle Genetics, Inc.
Investors:
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
or
Media:
Tricia Larson, 425-527-4180
tlarson@seagen.com

Recent Stories

RSS feed for Seattle Genetics, Inc.

Seattle Genetics, Inc.